- Home
- ZLAB vs IVT Comparison
ZLAB vs IVT Comparison
Compare ZLAB & IVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- IVT
- Stock Information
- Founded
- ZLAB 2013
- IVT 2005
- Country
- ZLAB China
- IVT United States
- Employees
- ZLAB N/A
- IVT N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- IVT Real Estate Investment Trusts
- Sector
- ZLAB Health Care
- IVT Real Estate
- Exchange
- ZLAB Nasdaq
- IVT Nasdaq
- Market Cap
- ZLAB 1.8B
- IVT 2.2B
- IPO Year
- ZLAB 2017
- IVT N/A
- Fundamental
- Price
- ZLAB $26.36
- IVT $29.64
- Analyst Decision
- ZLAB Strong Buy
- IVT Buy
- Analyst Count
- ZLAB 5
- IVT 3
- Target Price
- ZLAB $56.21
- IVT $31.33
- AVG Volume (30 Days)
- ZLAB 768.6K
- IVT 810.9K
- Earning Date
- ZLAB 11-12-2024
- IVT 10-29-2024
- Dividend Yield
- ZLAB N/A
- IVT 3.05%
- EPS Growth
- ZLAB N/A
- IVT 51.48
- EPS
- ZLAB N/A
- IVT 0.09
- Revenue
- ZLAB $322,711,000.00
- IVT $290,167,000.00
- Revenue This Year
- ZLAB $48.34
- IVT N/A
- Revenue Next Year
- ZLAB $47.12
- IVT $4.76
- P/E Ratio
- ZLAB N/A
- IVT $329.18
- Revenue Growth
- ZLAB 28.16
- IVT 14.12
- 52 Week Low
- ZLAB $13.48
- IVT $23.53
- 52 Week High
- ZLAB $31.22
- IVT $30.33
- Technical
- Relative Strength Index (RSI)
- ZLAB 66.11
- IVT 58.75
- Support Level
- ZLAB $23.96
- IVT $28.81
- Resistance Level
- ZLAB $27.37
- IVT $29.81
- Average True Range (ATR)
- ZLAB 1.26
- IVT 0.44
- MACD
- ZLAB -0.03
- IVT 0.05
- Stochastic Oscillator
- ZLAB 72.56
- IVT 90.26
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.